HomeStocksJAGSNPHARM

J

Jagsonpal Pharmaceuticals

JAGSNPHARM Share Price

Healthcare
mtf MTF 2.00x

227.84

10.80 (4.98%)profit

as on 02 Apr 2025 at 15:29

1D
Bulb

Today Jagsonpal Pharmaceuticals opened at 217.50 while its previous close was at 217.04. In todays trading session JAGSNPHARM reached a high of 230.97 and low of 214.60. The average traded price for today is 225.56. The 50 DMA stands at 226.16 and 200 DMA is at 199.48. Looking at intraday trend, the stock is in Uptrend.

TradingView Logo

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

JAGSNPHARM Stock Performance

Markets Today

High

230.97

Low

214.60

Open at

217.50

Prev Close

217.04

Volumes

1,28,611

Avg Price

225.56

Lower Circuit

173.63

Upper Circuit

260.44

Last Traded Details

Quantity

455

Time

15:29:51

Price Movement

214.60
227.84
230.97
Loss 6.17%down side
up side1.36% profit

Historical Performance

3 M High

284.36

3 M Low

196.35

1 Yr High

328.04

1 Yr Low

110.00

3 Yr High

328.04

3 Yr Low

100.72

5 Yr High

328.04

5 Yr Low

6.70

1-Year Performance

110.00
227.84
328.04
loss6.17%down side
up side1.36% profit

JAGSNPHARM Latest News

news

No news for this stock at the moment.


JAGSNPHARM Share Price History

Close Price

Volume

JAGSNPHARM share price in last 10 trading sessions

DayOpenCloseChange%Day HighDay LowVolume
01 Apr 2025217.90217.04
-0.07% Loss
220.28211.2188,625
28 Mar 2025223.00217.20
-2.44% Loss
225.10215.051,02,476
27 Mar 2025214.40222.50
5.15% profit
225.00210.612,15,962
26 Mar 2025212.99211.05
-1.31% Loss
218.18209.6068,802
25 Mar 2025222.60213.81
-3.62% Loss
225.00212.131,03,570
24 Mar 2025222.79221.55
-0.52% Loss
226.78219.591,01,078
21 Mar 2025224.15222.70
-0.25% Loss
228.95222.001,03,903
20 Mar 2025223.00223.25
0.90% profit
227.08217.2592,216
19 Mar 2025216.90221.25
1.97% profit
225.51215.301,08,966
18 Mar 2025205.56216.90
5.23% profit
219.00205.561,10,843

JAGSNPHARM Fundamentals

View Fundamentals arrow

Company Valuation

Market Cap (₹ Cr.)

1,441

PE Ratio

39.60

PB Ratio

7.31

Dividend Yield

0.92%

ROE

11.99%

ROCE

15.50%

Book Value (₹)

29.70

Face Value (₹)

2.00


Share Holding Pattern

Held ByDec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters
68.48%68.09%68.04%67.97%67.81%
Domestic Institutional Investors (DII)
0.00%0.85%0.85%0.11%0.00%
Foreign Institutional Investors (FII)
0.00%0.73%1.10%2.30%2.10%
Public Investors
21.94%20.69%20.79%20.38%20.64%
Government
0.00%0.00%0.00%0.00%0.00%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government


JAGSNPHARM Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

SIP Logo

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.


JAGSNPHARM Technicals

View Technicals arrow

Moving Averages

PeriodSimpleSignal
5-SMA216.32Bullish
10-SMA218.73Bearish
20-SMA214.68Bullish
50-SMA226.16Bearish
100-SMA239.77Bearish
200-SMA199.48Bullish

Technical Indicators

IndicatorValueAction
RSI(14)48.57Neutral
ATR(14)11.82Less Volatile
STOCH(9,6)52.38Neutral
STOCH RSI(14)79.11Neutral
MACD(12,26)1.27Bullish
ADX(14)16.72Weak Trend

Summary of Technical Indicators for JAGSNPHARM


JAGSNPHARM Financials Summary
Revenue

In Crores

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
50466376100
EBITDA

In Crores

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
6581841

Net Profit

In Crores

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
4451232
EPS
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
1.481.311.944.294.74

JAGSNPHARM Financials

Income Statement

In Crores

Quarterly StatementDec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Revenue50466376100
Expenses4441555858
Operating Profit3371616
Operating Profit Margin %7%6%11%22%21%
Other Income331226
Interest00000
Depreciation00122
Profit Before Tax5571539
Tax %0%0%0%0%0%
Net Profit4451232
EPS11245

Balance Sheet

In Crores

Yearly Balance SheetMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Share Capital1313131313
Reserve & Surplus98109120146174
Non Current Liabilities325911
Current Liabilities3340272819
Total Liabilities147164164195217
Fixed Assets222623249
Capital Work in Progress40000
Investments11155110
Other Assets10912391170208
Total Assets147164164195217

Cash Flow

In Crores

Yearly Cash FlowMar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Operating Activities112874735
Investing Activities-11-2-26-58-25
Financing Activities-1-7-18-1-9
Net Cash Flow-119-36-122
ScanX Logo

Get In-depth View of JAGSNPHARM Quaterly Results, Balance Sheet, Cashflows & Corporate Action.

Use Screener

Corporate Actions

DateCorporate ActionInformation
08 Jan 2025
SPLIT
2:5

JAGSNPHARM Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2023-24218
-11.83% Loss
23
-15.94% Loss
FY 2022-23242
8.79% profit
27
41.72% profit
FY 2021-22221
15.77% profit
19
10.53% profit

Top Mutual Funds Invested in JAGSNPHARM

logo

WhiteOak Capital Pharma and Healthcare Fund Direct - Growth

AUM

₹ 271 Cr.

1Y Returns

26.87 %

3Y Returns

0.00 %

5Y Returns

0.00 %







What’s New In The Market
H

Honasa Consumer Ltd: Mamaearth Launches Mosquito Repellent Campaign with Shilpa Shetty

sentiment_img

Mamaearth, owned by Honasa Consumer Ltd, launched a new marketing campaign for its mosquito repellent range featuring Shilpa Shetty Kundra. The campaign, released on April 2, 2025, promotes natural mosquito protection for children. Honasa Consumer Ltd shares were trading at ₹235.80, up 0.53% on NSE.

HONASA

236.04

1.49
(0.64%) profit
9 minutes ago

W

Welspun Corp: Expansion and Diversification Drive Growth Prospects

sentiment_img

Welspun Corp expands into building materials, plans plastic pipes launch, and announces ₹1,660 crore expansion in Saudi Arabia. The company has a strong order book of ₹20,000 crore, with 60% from the high-margin US market. Management guides for FY2025 EBITDA of ₹1,700 crore, with potential upside. Stock up 22.19% in the past month.

WELCORP

849.35

1.15
(0.14%) profit
17 minutes ago

P

One 97 Communications: Paytm Shares Surge 3% to 6-Week High, Up 25% in 15 Sessions

sentiment_img

Paytm shares hit a 6-week high of ₹822.70, rising 25% in 15 trading sessions. The company partnered with Greater Hyderabad Municipal Corporation for property tax collection. Paytm Money received SEBI approval to act as a research analyst. JM Financial maintains 'Buy' rating with a target price of ₹1,010.

PAYTM

817.95

16.85
(2.10%) profit
2 hours ago

FAQs

Jagsonpal Pharmaceuticals share price as of today is ₹ 227.84 as on 02 Apr 2025 at 15:29.
The 52W high of Jagsonpal Pharmaceuticals is ₹ 328.04 and 52W low is ₹ 110.00 as of 02 Apr 2025 at 15:29.
The past returns of Jagsonpal Pharmaceuticals share are -
  • Past 1 year: 89.46%
  • Past 3 years: 67.33%
  • Past 5 years: 3,109.01%
The PE and PB ratio of Jagsonpal Pharmaceuticals stands at 39.60 and 7.31 respectively as on 02 Apr 2025 at 15:29.
The EPS of Jagsonpal Pharmaceuticals is 0.00 for the quarter ended 0.00 and 0.00 for the financial year 0.00.
The shareholding pattern of Jagsonpal Pharmaceuticals is as follows:
  • DIIs - 0.00%
  • FII - 2.10%
  • Promoters - 67.81%
  • Public Investors 20.64%
  • Goverenment - 0.00%
Yes, you can buy shares of Jagsonpal Pharmaceuticals online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Jagsonpal Pharmaceuticals stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Jagsonpal Pharmaceuticals share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Jagsonpal Pharmaceuticals.
You can easily buy the shares of Jagsonpal Pharmaceuticals even after the markets are closed using the After Market Order feature on Dhan Trading App.
Candle bars with Screen
Invest in JAGSNPHARM
Candle bars with Screen

Pay Zero Brokerage on Delivery

Candle bars with Screen

Open FREE Demat Account

Indian Flag

+91

Or Scan the QR Code to download the Dhan App

QR code Logo


Invest & Trade with a Trading
Platform That's icon

Open your Dhan Account in minutes!


border

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2025 Moneylicious Securities Private Limited. All rights reserved. CIN: U74999MH2012PTC433549 Moneylicious Securities is part of Raise Financial Services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India.
Corporate Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India. Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Moneylicious Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client in the chat section are for support purposes only, and any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Moneylicious Securities Private Limited. All DHAN clients are registered under Moneylicious Securities Private Limited. Clients are advised to refer to our company as Moneylicious Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / Moneylicious / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Moneylicious Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Saarthi 2.0 Mobile App for Investors